Evotec AG (NASDAQ:EVTCY) Stock Rating Reaffirmed by DZ Bank AG

Evotec AG (OTCMKTS:EVTCY)‘s stock had its “sell” rating restated by equities researchers at DZ Bank AG in a research report issued on Wednesday, November 8th.

Several other equities analysts have also commented on the company. Zacks Investment Research lowered Evotec from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Roth Capital reiterated a “buy” rating on shares of Evotec in a research note on Tuesday, July 25th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $68.00.

Shares of Evotec (OTCMKTS:EVTCY) opened at $29.66 on Wednesday. Evotec has a 12-month low of $12.30 and a 12-month high of $52.82. The stock has a market capitalization of $2,310.52, a price-to-earnings ratio of 61.76, a PEG ratio of 3.76 and a beta of 0.53.

ILLEGAL ACTIVITY WARNING: “Evotec AG (NASDAQ:EVTCY) Stock Rating Reaffirmed by DZ Bank AG” was first published by BBNS and is owned by of BBNS. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://baseballnewssource.com/markets/evotec-ags-evtcy-sell-rating-reaffirmed-at-dz-bank-ag/1767956.html.

Evotec Company Profile

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.